Protein Stability After Administration: A Physiologic Consideration.

Area of Science:

• Biopharmaceutical development
• Protein stability assessment
• Drug product characterization

Background:

• Therapeutic proteins (TPs) can degrade significantly in vivo due to unique physiological conditions, impacting patient safety and drug efficacy.
• Existing drug product (DP) stability assessments may not accurately reflect in vivo protein behavior.
• Regulatory authorities and scientists emphasize the need for robust in vivo stability monitoring.

Purpose of the Study:

• To highlight the importance of evaluating in vivo stability of therapeutic proteins (TPs) during early drug development.
• To introduce the utility of advanced in vitro models for simulating physiological conditions and predicting in vivo protein behavior.
• To advocate for integrating in vivo stability assessments into holistic stability testing strategies.

Main Methods:

• Development and application of advanced in vitro models to simulate physiological conditions relevant to specific administration routes.
• Benchmarking of drug product (DP) candidates using in vitro models to identify potential liabilities.
• Correlation of in vitro stability data with anticipated in vivo protein behavior.

Main Results:

• In vitro models can effectively simulate physiological conditions, enabling early evaluation of TP stability.
• Early identification of molecular liabilities through in vitro-in vivo correlation studies can guide molecule optimization.
• Simulated in vivo stability assessments can accelerate development timelines.

Conclusions:

• In vivo stability assessment is critical for ensuring the safety and efficacy of therapeutic proteins (TPs).
• Advanced in vitro models offer a valuable tool for predicting in vivo protein behavior prior to extensive preclinical and clinical studies.
• Integrating in vivo stability evaluations early in development leads to more stable drug products (DPs) and improved patient outcomes.